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http://www.biomedcentral.com/1471-2407/14/623RESEARCH ARTICLE Open AccessPolysialic acid is associated with better prognosis
and IDH1-mutation in diffusely infiltrating
astrocytomas
Katri Mäkelä1,2*, Kristiina Nordfors2,3, Jukka Finne4, Anne Jokilammi5, Timo Paavonen1,2, Hannu Haapasalo1,2,
Miikka Korja6,7 and Joonas Haapasalo2,8Abstract
Background: The aim of the study was to assess the localization of Polysialic acid (polySia) and Neural cell
adhesion molecule (NCAM) in grade I–IV astrocytomas by confocal microscopy, and also to clarify and compare
their relationship to conventional clinicopathological features in these tumors.
Methods: Study material was stained immunohistochemically for polySia, NCAM and IDH1-R132H point mutation.
Confocal microscopy of polySia and NCAM staining was performed on tissue micro-array samples (TMA) of 242
diffusely infiltrating astrocytomas (grade II: 28; grade III: 33; grade IV: 181) and 82 pilocytic astrocytomas. The results
were statistically correlated to clinicopathological factors and survival data.
Results: PolySia was observed in 45 cases (19%) and NCAM positivity in 92 cases (38%). All 45 tumors with polySia
positivity were also positive for NCAM whereas there were 47 tumors which contained positive staining for NCAM
but not for polySia. The simultaneous expression was concomitant and colocalized suggesting polysialyated NCAM
(polySia-NCAM). PolySia expression was significantly stronger in IDH1 mutated tumors than in IDH1 non-mutated
(p = 0.001, chi-square test). There were no significant differences in polySia-NCAM between primary tumors or
recurrences (p = n.s., chi-square test). PolySia positivity was associated with longer patient survival in relation to total
tumor material (p = 0.020, log-rank test). Furthermore, when only glioblastomas were assessed, patients with
positive polySia had significantly better prognosis (p = 0.006, log-rank test). In multivariate survival analysis, polySia
was found to be an independent prognostic factor. PolySia was nearly absent in grade I pilocytic astrocytomas
(1 immunopositive tumor of 82).
Conclusions: Expression of polySia is common in adult grade II–IV astrocytomas, whereas it is nearly absent in
pediatric grade I pilocytic astrocytomas. PolySia positivity is associated with longer survival rates in patients with a
grade II–IV astrocytomas and also grade IV glioblastomas assessed separately. The results of this study suggest that
IDH1 mutation may be associated with polySia expression pathways in malignant gliomas.
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Diffusely infiltrating astrocytomas are central nervous
system (CNS) tumors originating from astrocytic glial
cells, or their precursors. They represent an important
tumor entity accounting for 60% of all primary brain tu-
mors [1]. Diffusely infiltrating astrocytomas can be as-
sorted into grades II – IV according to WHO criteria.
The most malignant type, glioblastoma (GBM), is the
most prevalent form in adult patients. The devastat-
ing nature of GBM is highlighted by the 5-year sur-
vival rate of 10% even with using the latest therapeutical
methods [2]. Lower grade astrocytomas most often re-
lapse and proceed towards the more malignant grade.
Primary GBMs most commonly occur as a new onset
disease, whereas secondary GBMs develop from lower
grade astrocytomas. Grade I astrocytomas are called
pilocytic astrocytomas. They are considered benign as
they have a clear borderline and are generally slow
growing.
Neural cell adhesion molecule (NCAM) mediates ad-
hesion between adjacent neurons and glial cells [3,4].
Polysialic acid (polySia) is a carbohydrate polymer, which
is added post-translationally to the extracellular part of
NCAM, hence locating on the cell surface [5]. PolySia is
a strongly hydrated and negatively charged molecule. By
binding to NCAM, it increases the hydrodynamic area
of the cells extern proximity and impairs the capability
of NCAM to maintain the cell adhesion structures be-
tween other cells and the ECM [3,6]. In normal tissues,
especially during embryonic development, polySia takes
part in neuronal cell migration and axon pathfinding [7].
In this way, polySia can facilitate cell migration and plas-
ticity as well as increase the cell’s invasion capability [8].
In adulthood, polySia expression has mainly been associ-
ated with various pathologies, such as, for example, poor
patient outcome and increasing WHO grade in astro-
cytic tumors [9,10]. In contrast, NCAM expression has
been shown to correlate with lower malignancy grade
and better patient outcome [11,12].
As polysialylated NCAM (polySia-NCAM) is con-
sidered to be a neural stem cell marker [13], and dif-
fusely infiltrating astrocytomas are often referred as
stem cell cancers [1], we studied for the first time whe-
ther the characteristics and clinical course of astrocyto-
mas with and without polysialylated NCAM differ from
each other. In addition, given that the isocitrate de-
hydrogenase 1 (IDH1) mutation has been found to be an
essential genetic aberration in grade II–III diffusely infil-
trating astrocytomas and especially in secondary GBMs
[14,15], we wanted to study whether this stem cell mar-
ker, polySia-NCAM, can be of additional help in iden-
tifying the prognostic characteristics if grade II-IV
astrocytomas and secondary GBMs with and without
IDH1 mutations.Methods
Study material
There were 242 diffusely infiltrating astrocytomas (grade
II: 28; grade III: 33; grade IV: 181) and 82 grade I pilocytic
astrocytomas. 187 were primary astrocytomas and 55 were
recurrences. Of the grade IV astrocytomas, 10 were glio-
sarcomas, 1 was a gliant cell glioblastoma and 170 were
glioblastomas. Astrocytoma specimens were initially fixed
in 4% phosphate-buffered formaldehyde and then pro-
cessed into paraffin blocks. On the basis of hematoxylin
and eosin-stained slides, a neuropathologist (H.H.) evalu-
ated the tumors according to WHO 2007 criteria [1]. One
histologically representative tumor region was selected
from each specimen. From the selected regions, 1000 μm
tissue cores were mounted into tissue microarray blocks
using a custom made instrument (Beecher Instruments,
Silver Spring, MD, USA). Samples were obtained from
surgically operated patients at the Tampere University
Hospital, Tampere, Finland, during the years 1983 to 2001.
Tumors were radically resected if possible and most pa-
tients with high grade astrocytomas also received radio-
therapy. Patient survival was examined by a follow-up
study. Follow-up time started after primary resection of
the astrocytoma. Patients’s progress was followed up to the
year 2012 or until they were deceased. The study protocol
was approved by the ethical committee of Tampere Univer-
sity Hospital and the National Authority for Medicolegal
Affairs of Finland (diary number7796/05.01.00.06/2011).
PolySia-binding fluorescent fusion protein (EndoNA2-
GFP) at a concentration of 10 μg/ml was used for polySia
detection. Mouse anti-human NCAM antibody (123C3) at
a concentration of 4 μg/ml (Santa Cruz Biotechnology,
Santa Cruz, CA) was used as a primary antibody. Immu-
nohistochemical incubations were done overnight at 4°C.
In immunofluorescence, Alexa Fluor 594 chicken anti-
mouse secondary antibodies (Molecular Probes, Eugene,
OR) were used, and slides were mounted with Immu-
Mount (Shandon, USA). Confocal microscopy was per-
formed as described earlier [16]. The analysis was done
for the TMA of the 242 paraffin-embedded diffusely
infiltrating astrocytoma samples. A Leica TCS SP MP
confocal microscope equipped with a Spectra-Physics
Tsunami Ti-sapphire laser and Leica confocal software
was used in analysis. Sections were examined at two exci-
tation wavelengths: 488 nm for polySia-binding fusion
protein EndoNA2-GFP and 546 nm for fluorescent sec-
ondary antibodies.
R132H point mutation specific mouse monoclonal anti-
body (Dianova GmbH, Hamburg, Germany) was used to
detect IDH1-R132H specific gene mutations. Fully auto-
mated immunostaining was performed by a Bondmax im-
munostainer (Leica Biosystems Newcastle Ltd, Newcastle
upon Tyne, United Kingdom). Bond Dewax Solution
(catalogue No. AR9222) was used for deparaffinisation.
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pH 5.9-6.1 (catalogue No. AR9961) was used for 30 min at
100°C. The slides were incubated for 30 minutes at room
temperature with the IDH1-R132H point mutation spe-
cific antibody (dilution 1:50). The staining kit used was
Bond Refine Detection kit. The slides were rinsed between
steps with Bond Wash Solution (catalogue No. AR9590).
EGFR amplification status was examined by chromo-
genic in situ hybridisation (CISH) [17]. The cell prolifera-
tion index Ki-67/MIB-1 and p53 immunohistochemistry
were performed and analysed as previously described
[18,19].
Statistical analysis
The statistical analysis was performed using IBM SPSS
Statistics version 20.0. Significant associations were de-
fined using the chi-square test and Mann–Whitney U-test
and Kruskall-Wallis test. Kaplan-Meier curves and log-
rank test were used in univariate survival analyses. Cox
Regression analysis was used for multivariate survival
analyses.
Results
PolySia positivity was observed in 45 (18.6%) cases of
242 grades II – IV diffusely infiltrating astrocytomas. 92
(38.0%) tumors were shown to be positive for NCAMFigure 1 Staining patterns of polysialic acid and NCAM. A positive exp
shown in figure A, and positive NCAM expression in figure B in glioblastom
polysialic acid and NCAM in same tumor sample (C). Negative staining of p
D and E (F) in pilocytic atrocytoma. Scale bar, 40 μm.and 150 were negative. All tumors with polySia positivity
were also shown to be positive for NCAM, whereas there
were 47 tumors, which contained positive staining for
NCAM but not for polySia. The simultaneous expression
was concomitant and colocalized to cell surfaces indi-
cating polysialylated NCAM. Figure 1 demonstrates the
staining patterns of polySia and NCAM observed by con-
focal microscopy.
PolySia nor NCAM expression were not associated
with WHO grade. Table 1 shows the numbers of polySia
and NCAM positive tumors in each WHO grade. There
was no correlation between polySia-NCAM expression
and primary vs. recurrent tumors (p = n.s, chi-square test).
PolySia was not associated with p53 expression or EGFR
amplification (p = n.s., chi-square test).
Interestingly, tumors having IDH1 mutation were more
often polySia-NCAM positive (p = 0.001, chi-square test):
in IDH1 mutated tumors there were 31 polySia positive
and 18 negative cases, whereas, in IDH1 non-mutated
tumors, there were 120 positive and 19 negative cases.
Similarly, NCAM positive tumors were more often IDH1
mutated (p = 0.001, chi-square test; IDH1 mutated: 20
negative and 29 positive for NCAM, IDH1 non-mutated:
94 negative and 45 positive for NCAM). Positive polySia
expression was also associated with increasing prolifera-
tion by MIB-1 / Ki-67 (p = 0.007, Kruskall-Wallis test).ression of polysialic acid detected with EndoNA2-GFP fusion protein is
a. Overlay image of A and B showing the colocalized expression of
olysialic acid (D), positive staining for NCAM (E), and overlay image of
Table 1 Numbers of NCAM and polySia positive tumors in
different WHO grades (p = n.s.)
WHO grade
II III IV Total
NCAM
Positive 9 (32.2%) 18 (54.5%) 65 (35.9%) 92
Negative 19 (67.8%) 15 (45.5%) 116 (64.1%) 150
PolySia
Positive 2 (7.1%) 8 (24.2%) 35 (19.3%) 45
Negative 26 (92.9%) 25 (75.8%) 146 (80.7%) 197
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median follow up time of survivors was 133 months.
When all grade II – IV astrocytomas were included within
the analysis, polySia positivity was associated with better
patient prognosis (p = 0.020, log-rank test, Figure 2). In
glioblastomas, positive polySia expression was associated
significantly with better prognosis (p = 0.005, log-rank
test, Figure 3). NCAM expression also associated with
longer patient survival in total tumor material (p = 0.035,
loq-rank test), but not within different grades, when stud-
ied separately. However, when only glioblastoma patients
were analysed and both polySia and NCAM expression
was assessed simultaneously, patients with both polySia
and NCAM expression had longer survival rates than
patients with negative polySia and positive or negative
NCAM (p = 0.014, log-rank test). Furthermore, patientsFigure 2 Polysialic acid in grade II–IV astrocytomas (p = 0.020, log
183 patients were included in the analysis.with NCAM expressing tumors had the worst prognosis
compared to patients whose tumor was NCAM negative
or expressed both NCAM and polySia. When grade II and
III tumors were analysed separately, polySia or NCAM
were not associated with patient prognosis (p = n.s, log-
rank test).
Cox multivariate survival analysis was done with the
following variables: patient age, IDH1 mutation, EGFR
amplification, MIB1 labeling index, polySia expression,
NCAM expression and WHO grade. There were 77 cases
in which all these variables were known. The analysis was
not done separately in each WHO grade because the cases
included would have been few. IDH1 mutation, patient
age, MIB1 and polySia expression came up as independent
prognosticators. The hazard ratio (Exp(B)) for IDH1 was
0.195 (95% CI for Exp(B) 0.101-0.376). Exp(B) for patient
age was 1.705 (95% CI for Exp(B) 1.217-2.390). Exp(b) for
MIB1 was 1.673 (95% CI for Exp(B) 1.210-2.312). Exp(B)
for polySia was 0.516 (95% CI for Exp(B) was 0.280-
0.951). Age cut off poits were 0–54, 55–69, 70-. Cut
off points for MIB1 were 0–5, 5.1-15, 15.1-.
Polysialic acid in pilocytic astrocytomas
To assess the expression of polySia in grade I pilocytic
astrocytomas, we conducted analysis on those mostly pe-
diatric and benign tumors. Only one (1.2%) of the studied
82 tumors expressed polySia. In this case, polySia expres-
sion was located on the cell surfaces and it was histologi-
cally associated with NCAM (polySia-NCAM). NCAM-rank test). The patients with positive polySia had best prognosis.
Figure 3 Survival in glioblastomas by polysialic acid expression. The patients with positive polySia-NCAM had significantly better prognosis
(p = 0.006, log-rank test). 143 patients were included in the analysis.
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pilocytic astrocytoma is demonstrated in Figure 1.
Discussion
PolySia is commonly expressed in grade II – IV astro-
cytomas and it is bound to NCAM, whereas it is nearly
absent in grade I pilocytic astrocytomas. Patients with
polySia expressing astrocytomas had better prognosis than
patients with polySia negative astrocytomas. Furthermore,
when only glioblastomas were studied, patients with tu-
mors of polySia-NCAM positivity had similarly better
prognosis. In multivariate survival analysis polySia came
up as an independent prognostic factor, indicating better
prognosis. Finally, polySia expression associated with one
of the key features in gliomas, IDH1 mutation. When
IDH1 mutation and polySia expression were assessed sim-
ultaneously, the patients with both polySia expressing and
IDH1 mutatated tumors had the best prognosis. Although
polySia was associated with better prognosis in univariate
and multivariate analysis, it was also associated with in-
creasing proliferation. This underlines that mechanisms in
protein expressions are complex.
Association of polySia expression with malignant tu-
mors such as astrocytomas has been reported previously
[9,10]. However, the prognostic significance of histologi-
cally evaluated polySia expression in survival analyses
was studied here for the first time. Similar to our find-
ings in astrocytomas, polySia-NCAM expression is as-
sociated with better prognosis in neuroblastomas [16],which are also heterogenous tumors with stem cell-like
characteristics. As speculated before, polySia-NCAM as
a neural stem cell marker provides tumor cells not only
with proliferative and mitotic characteristics but also
with differentiation capability, like in the developing brain,
thus improving prognosis [16]. Interestingly, patients with
astrocytomas expressing only NCAM but not polySia had
even worse prognosis than patients whose tumors were
negative for both NCAM and polySia. Whether polySia
expression prevents unfavorable effects of NCAM, such as
leading cells towards epithelial-mesenchymal transition
(EMT), or repress the intercellular connections mediated
by NCAM through creating a hydrophilic radius on the
cell surface, is speculative, but polySia expression may be
an additional prognostic marker in most unfavorable as-
trocytomas, like in most unfavorable neuroblastomas [16].
Previously, Petridis et al. [9] as well as Amoureux et al.
[10], have presented correlations between polySia ex-
pression and tumor malignancy in astrocytomas. In the
study of Petridis et al., biopsies from 30 patients with
astrocytomas I – IV were evaluated. The statistical
analyses were performed combining grades I and II astro-
cytomas as one group and grades III and IV as another.
They showed that higher grade astrocytomas were more
often polySia positive. Given that we found only one out
of 82 pilocytic astrocytomas as polySia-NCAM positive,
the previous finding is not surprising. Since the biological
background of pilocytic astrocytomas differs from malig-
nant astrocytomas, the finding of Petridis et al. could be
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use polySia-NCAM antibodies in immunohistochemical
stainings of astrocytomas, since positive staining very
likely rules out the possiblity of pilocytic astrocytomas. In
this study, larger patient population, longer patient follow
up time, confocal microscopy describing the anatomical
location, and importantly, assessment of IDH mutation
might provide additional value to the analysis.
Petridis et al. also suggested in their study that the path-
ways of regulation of polySia expression are mostly un-
known and should be examined in future studies. In our
study, polySia expression was shown to be associated with
IDH1 mutation, one of the key features of astrocytomas.
Interestingly, IDH1 mutation has recently been linked to
EMT. In EMT, cells transform to a mesenchymal-like
form and loose e-cadherin mediated cell-to-cell adhesions.
EMT enables epithelial tumors to progress into metastatic
cancers. Grassian et al. showed that high levels of the
oncometabolite 2-HG, produced by mutant IDH1 enzyme,
cause an epithelial-mesenchymal transition -like pheno-
type in IDH1 mutated cells by changing the EMT-related
gene expression and cellular morphology [20]. Also, both
increased NCAM and polySia expression have been con-
nected to EMT mainly via causing loss of the cell-to-cell
adhesion molecule e-cadherin [21-23]. Thus, it is possible
that IDH1 mutation takes part in the regulation pathways
of polySia-NCAM expression and should perhaps be fur-
ther studied as a controlling factor of polySia-NCAM ex-
pression. Also, since polySia-NCAM has been proposed
to be a marker of stem cells, another interesting theme for
future research would be to study the expression of poly-
Sia and NCAM and their colocalisation in specific cellular
subpopulations of diffusely infiltrating astrocytomas.
Conclusion
PolySia expression in astrocytomas, and remarkably, in
glioblastomas, was associated with longer overall survival
rates. Since polySia expression is significantly more com-
mon in IDH1 mutated tumors, and since these tumors
have better overall prognosis, polySia may be a new addi-
tional molecular marker in the prognostic caharcterization
of glioblastomas.
Abbreviations
CNS: Central nervous system; GBM: Glioblastoma multiforme; IDH1: Isocitrate
dehydrogenase 1; NCAM: Neural cell adhesion molecule; ECM: Extracellular
matrix; polySia: Polysialic acid; EMT: Epithelial-mesenchymal transition;
2-HG: 2-hydroxyglutarate.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
All authors were involved in the design of the study, drafting and writing
the manuscript and approved the final version of the manuscript. In addition
KM, KN, MK and JH carried out confocal microscopy procedures,
immunohistochemistry procedures, analysis of the study material, and
statistical analysis. All authors read and approved the final manuscript.Acknowledgements
We would like to thank Mrs Satu Salo and Ms Eini Eskola for skilful technical
assistance. The study was supported by the Competitive Research Funding
of the Tampere Medical Research Fund of Tampere University Hospital and
the Academy of Finland. This study was also supported by personal grants
awarded by the Sigrid Jusélius Foundation, Emil Aaltonen Foundation,
Biomedicum Helsinki Foundation, Orion-Farmos Research Foundation,
Instrumentarium Research Foundation, and Finnish Medical Foundation
to M.K.
Author details
1University of Tampere, School of Medicine, Biokatu 6, 33520 Tampere,
Finland. 2Department of Pathology, Fimlab Laboratories, Biokatu 4, PL 2000,
33521 Tampere, Finland. 3Department of Pediatrics, Tampere University
Hospital, Teiskontie 35, 33521 Tampere, Finland. 4Department of Biosciences,
Division of Biochemistry and Biotechnology, University of Helsinki, P.O.B. 56,
FI 00014 Helsinki, Finland. 5Department of Medical Biochemistry and
Genetics, University of Turku, Kiinamyllynkatu 10, 20520 Turku, Finland.
6Department of Neurosurgery, Helsinki University Central Hospital, P.O. Box
266, FI-00029 Helsinki, Finland. 7Australian School of Advanced Medicine, 2
Technology Place, Macquarie University, Suite 201, Sydney NSW 2109,
Australia. 8Unit of Neurosurgery, Tampere University Hospital, Teiskontie 35,
33521 Tampere, Finland.
Received: 7 February 2014 Accepted: 21 August 2014
Published: 28 August 2014References
1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK: WHO Classification of
Tumours of the Central Nervous System. Lyon: IARC; 2007.
2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC,
Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J,
Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T,
Weller M, Lacombe D, Cairncross JG, Mirimanoff RO: Effects of radiotherapy
with concomitant and adjuvant temozolomide versus radiotherapy
alone on survival inglioblastoma in a randomised phase III study: 5-year
analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10:459–466.
3. Seifert A, Glanz D, Glaubitz N, Horstkorte R, Bork K: Polysialylation of the
neural cell adhesion molecule: interfering with polysialylation and
migration in neuroblastoma cells. Arch Biochem Biophys 2012, 524:56–63.
4. Dallérac G, Rampon C, Doyère V: NCAM function in the adult brain:
lessons from mimetic peptides and therapeutic potential. Neurochem Res
2013, 38:1163–1173.
5. Finne J, Finne U, Deagostini-Bazin H, Goridis C: Occurrence of alpha 2–8
linked polysialosyl units in a neural cell adhesion molecule. Biochem Biophys
Res Commun 1983, 112:482–487.
6. Rutishauser U: Polysialic acid at the cell surface: biophysics in service of
cell interactions and tissue plasticity. J Cell Biochem 1998, 70:304–312.
7. Brusés JL, Rutishauser U: Roles, regulation, and mechanism of polysialic
acid function during neural development. Biochimie 2001, 83:635–643.
8. Suzuki M, Suzuki M, Nakayama J, Suzuki A, Angata K, Chen S, Sakai K,
Hagihara K, Yamaguchi Y, Fukuda M: Polysialic acid facilitates tumor
invasion by glioma cells. Glycobiology 2005, 15:887–894.
9. Petridis AK, Wedderkopp H, Hugo HH, Maximilian Mehdorn H: Polysialic
acid overexpression in malignant astrocytomas. Acta Neurochir (Wien)
2009, 151:601–604.
10. Amoureux MC, Coulibaly B, Chinot O, Loundou A, Metellus P, Rougon G,
Figarella-Branger D: Polysialic acid neural cell adhesion molecule
(PSA-NCAM) is an adverse prognosis factor in glioblastoma, and
regulates olig2 expression in glioma cell lines. BMC Cancer 2010, 10:91.
11. Todaro L, Christiansen S, Varela M, Campodónico P, Pallotta MG, Lastiri J,
Sacerdote de Lustig E, Bal de Kier Joffé E, Puricelli L: Alteration of serum
and tumoral neural cell adhesion molecule (NCAM) isoforms in patients
with brain tumors. J Neurooncol 2007, 83:135–144.
12. Duenisch P, Reichart R, Mueller U, Brodhun M, Bjerkvig R, Romeike B,
Walter J, Herbold C, Regenbrecht CR, Kalff R, Kuhn SA: Neural cell adhesion
molecule isoform 140 declines with rise of WHO grade in human
gliomas and serves as indicator for the invasion zone of multiform
glioblastomas and brain metastases. J Cancer Res Clin Oncol 2011,
137:399–414.
Mäkelä et al. BMC Cancer 2014, 14:623 Page 7 of 7
http://www.biomedcentral.com/1471-2407/14/62313. Pennartz S, Belvindrah R, Tomiuk S, Zimmer C, Hofmann K, Conradt M,
Bosio A, Cremer H: Purification of neuronal precursors from the adult
mouse brain: comprehensive gene expression analysis provides new
insights into the control of cell migration, differentiation, and
homeostasis. Mol Cell Neurosci 2004, 25:692–706.
14. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P,
Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S,
Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J,
Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD,
Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE,
Kinzler KW: An integrated genomic analysis of human glioblastoma
multiforme. Science 2008, 321:1807–1812.
15. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A:
Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol
2008, 116:597–602.
16. Korja M, Jokilammi A, Salmi TT, Kalimo H, Pelliniemi TT, Isola J, Rantala I,
Haapasalo H, Finne J: Absence of polysialylated NCAM is an unfavorable
prognostic phenotype for advanced stage neuroblastoma. BMC Cancer
2009, 9:57.
17. Tanner M, Gancberg D, Di Leo A, Larsimont D, Rouas G, Piccart MJ,
Isola J: Chromogenic in situ hybridization: a practical alternative for
fluorescence in situ hybridization to detect HER-2/neu oncogene
amplification in archival breast cancer samples. Am J Pathol 2000,
157:1467–1472.
18. Sallinen PK, Haapasalo HK, Visakorpi T, Helén PT, Rantala IS, Isola JJ, Helin HJ:
Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA,
and S-phase fraction using archival paraffin-embedded samples. J Pathol
1994, 174:275–282.
19. Haapasalo H, Sallinen S, Sallinen P, Helén P, Jääskeläinen J, Salmi TT, Paetau A,
Paljärvi L, Visakorpi T, Kalimo H: Clinicopathological correlation of cell
proliferation, apoptosis and p53 in cerebellar pilocytic astrocytomas.
Neuropathol Appl Neurobiol 1999, 25:134–142.
20. Grassian AR, Lin F, Barrett R, Liu Y, Jiang W, Korpal M, Astley H, Gitterman D,
Henley T, Howes R, Levell J, Korn JM, Pagliarini R: Isocitrate dehydrogenase
(IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-
dependent epithelial-mesenchymal transition (EMT). J Biol Chem 2012,
287:42180–42194.
21. Lehembre F, Yilmaz M, Wicki A, Schomber T, Strittmatter K, Ziegler D, Kren
A, Went P, Derksen PW, Berns A, Jonkers J, Christofori G: NCAM-induced
focal adhesion assembly: a functional switch upon loss of E-cadherin.
EMBO J 2008, 27:2603–2615.
22. Frame MC, Inman GJ: NCAM is at the heart of reciprocal regulation of
E-cadherin- and integrin-mediated adhesions via signaling modulation.
Dev Cell 2008, 15:494–496.
23. Schreiber SC, Giehl K, Kastilan C, Hasel C, Mühlenhoff M, Adler G, Wedlich D,
Menke A: Polysialylated NCAM represses E-cadherin-mediated cell-cell
adhesion in pancreatic tumor cells. Gastroenterology 2008, 134:1555–1566.
doi:10.1186/1471-2407-14-623
Cite this article as: Mäkelä et al.: Polysialic acid is associated with better
prognosis and IDH1-mutation in diffusely infiltrating astrocytomas. BMC
Cancer 2014 14:623.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
